INCY Profile
Incyte Corporation, a leading biopharmaceutical firm headquartered in Wilmington, Delaware, specializes in the discovery, development, and global commercialization of innovative therapeutics targeting hematology/oncology, inflammation, and autoimmunity. Operating across the United States, Europe, Japan, and other international markets, Incyte is renowned for its robust portfolio of proprietary drugs catering to diverse medical needs.
The company's flagship products include JAKAFI (ruxolitinib), approved for treating adults with intermediate or high-risk myelofibrosis, and MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), indicated for relapsed or refractory diffuse large B-cell lymphoma. PEMAZYRE (pemigatinib), another notable offering, serves as a fibroblast growth factor receptor kinase inhibitor targeting oncogenic drivers in various solid and liquid tumors. Additionally, ICLUSIG stands as a pivotal kinase inhibitor for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.
Incyte's robust pipeline includes promising clinical-stage candidates such as axatilimab, an anti-CSF-1R monoclonal antibody in development for chronic graft-versus-host disease (GVHD) and other immune-mediated disorders. The company also advances parsaclisib, a Phase II PI3Kd inhibitor for follicular lymphoma and other lymphomas, and retifanlimab, currently in Phase III trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, with Fast Track designation for metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer.
With strategic collaborations and licensing agreements with industry leaders like Novartis, Lilly, and Innovent, among others, Incyte Corporation continues to expand its therapeutic footprint. Founded in 1991, the company remains committed to pioneering breakthrough treatments and enhancing patient outcomes through cutting-edge biopharmaceutical research and development initiatives.
|
